Botulinum Toxin A for Chemotherapy-Induced Peripheral Neuropathy
This study is looking at whether IncobotulinumtoxinA (Xeomin®), a type of botulinum toxin, can help reduce pain from chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a common side effect of certain chemotherapy drugs, like those used for breast cancer, and can cause pain and discomfort. Researchers believe IncobotulinumtoxinA may work by blocking pain signals. You might be able to join if you are an adult with breast cancer who had taxane-based chemotherapy, developed neuropathic pain within six months of treatment, and score above 4 on a specific pain scale (DN4). The study will measure if your pain improves after eight weeks. The current status of this study is unclear, and it plans to enroll 40 participants.
- Study design
- This interventional study plans to enroll 40 participants. It compares IncobotulinumtoxinA injections to normal saline injections.
- What's involved
- Participants will receive one series of injections into either their hands or feet. Pain levels will be measured at the start of the study and again at eight weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- Pain improvement will be measured at eight weeks after the injections.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Improvement in pain from baseline at eight weeks as measured by the change in Neuropathic Pain Scale (NPS)baseline and 8 weeks
The primary outcome of this study will be the change pain as measured by the NPS at 8 weeks post intervention as compared to baseline NPS scores. The NPS is a validated scale that is used to classify patient's neuropathic pain. It includes assessment of global pain intensity and pain unpleasantness, two items addressing the location of the pain as deep or surface, and six items addressing the specific qualities of neuropathic such as sharp, hot, dull, cold, sensitivity, and itchy.